VNRX Volitionrx (VNRX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000093314
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
What the filings say about VNRX
Activist stakes (13D), 180 days
1 filing
Largest: 7.4% of the class
Volitionrx insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for VOLITIONRX LTD in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Oct 14, 2025.
- +0.8% median (+5.4% mean) 90-day return after 10 previous buys.
- The trade is 0.8% of the 2,554,847 shares held after it.
- No other insider bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Reynolds Cameron John bought about $7.0K of VNRX on Nov 17, 2025; 6 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Sep 12, 2025.
- +3.3% median (+8.9% mean) 90-day return after 9 previous buys.
- The trade is 4.3% of the 2,534,847 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Reynolds Cameron John bought about $56.1K of VNRX on Oct 14, 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Aug 5, 2025.
- +2.6% median (+9.6% mean) 90-day return after 11 previous buys.
- The trade is 9.0% of the 1,062,967 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Innes Guy Archibald bought about $49.0K of VNRX on Oct 14, 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 9, 2024.
- The trade is 3.1% of the 1,535,458 shares held after it.
- 2 other insiders bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STILL TIMOTHY I bought about $24.5K of VNRX on Oct 14, 2025; 2 other insiders bought within 30 days and 6 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Aug 5, 2025.
- +18.2% median (+17.0% mean) 90-day return after 8 previous buys.
- The trade is 0.6% of the 2,624,847 shares held after it.
- No other insider bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Reynolds Cameron John bought about $9.9K of VNRX on Sep 12, 2025; 6 funds added in the latest 13F quarter.61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
+40.0% year over year
more than 73% of Pharma & Biotech
Margin
-1352.2% net margin
below 89% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.5% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 66% of Pharma & Biotech
The situation: each line is one rule over one dataset
Lagoda Investment Management, L.P. disclosed a 5%+ stake (7.4%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VNRX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-97.8%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VNRX: institutional holders (13F)
13F holdings, latest reported quarter
1,455,950 sh
$2.0M
156,897 sh
$211.8K
55,537 sh
$75.0K
50,684 sh
$68.4K
45,000 sh
$60.8K
Congress trades in VNRX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Lagoda Investment Management, L.P.
Activist 13D · 2026-09-04
7.4%
Lagoda Investment Management, LLC
Activist 13D · 2026-09-04
7.4%
Fatima Dickey
Activist 13D · 2026-09-04
7.4%
VNRX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VNRX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$84.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$68.4K position · as of 2026-06-30
0.0%
Total Stock Market Index Trust
$794 position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$15.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$18.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VNRX financials
Revenue growth
+40.0%
XBRL, annual
Net margin
-1352.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VNRX
| FY Dec 2025 | $1.7M |
| FY Dec 2024 | $1.2M |
| FY Dec 2023 | $775.3K |
| FY Dec 2022 | $306.4K |
| FY Dec 2021 | $90.0K |
| Jun 2026 | $398.7K |
| Mar 2026 | $985.1K |
| Dec 2025 | $447.0K |
| Sep 2025 | $627.3K |
| Jun 2025 | $406.7K |
| Mar 2025 | $246.4K |
| Dec 2024 | $191.7K |
| Sep 2024 | $474.5K |
At each fiscal year end
Single quarter
Net margin, TTM
-1,043%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM VNRX
| FY Dec 2025 | -1,352% |
| FY Dec 2024 | -2,186% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,838% |
| Mar 2026 | -676.6% |
| Dec 2025 | -1,403% |
| Sep 2025 | -857.4% |
| Jun 2025 | -1,545% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -1,227% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$19.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VNRX
| FY Dec 2025 | -$19.8M |
| FY Dec 2024 | -$26.2M |
| FY Dec 2023 | -$19.1M |
| FY Dec 2022 | -$16.8M |
| FY Dec 2021 | -$21.8M |
| Jun 2026 | -$5.2M |
| Mar 2026 | -$5.3M |
| Dec 2025 | -$5.5M |
| Sep 2025 | -$3.6M |
| Jun 2025 | -$6.3M |
| Mar 2025 | -$4.3M |
| Dec 2024 | -$5.5M |
| Sep 2024 | -$5.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.17x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.77x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt VNRX
| FY Dec 2025 | -2.93x |
| FY Dec 2024 | -5.38x |
| FY Dec 2023 | -3.74x |
| FY Dec 2022 | -3.97x |
| FY Dec 2021 | -6.80x |
| Jun 2026 | -2.77x |
| Mar 2026 | -2.83x |
| Dec 2025 | -2.93x |
| Sep 2025 | -3.03x |
| Jun 2025 | -3.15x |
| Mar 2025 | -3.42x |
| Dec 2024 | -5.38x |
| Sep 2024 | -2.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -404.0% |
| FY Dec 2021 | -158.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-301.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VNRX
| FY Dec 2025 | -286.6% |
| FY Dec 2024 | -144.4% |
| FY Dec 2023 | -154.3% |
| FY Dec 2022 | -133.7% |
| FY Dec 2021 | -100.6% |
| Jun 2026 | -301.5% |
| Mar 2026 | -280.2% |
| Dec 2025 | -286.6% |
| Sep 2025 | -239.2% |
| Jun 2025 | -214.2% |
| Mar 2025 | -171.9% |
| Dec 2024 | -144.4% |
| Sep 2024 | -195.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -262.2% |
| FY Dec 2023 | -361.4% |
| FY Dec 2022 | -290.4% |
| FY Dec 2021 | -138.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -262.2% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.8M
market value at close 2026-10-27 on 2026-08-11 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value VNRX
| FY Dec 2025 | $644.2M |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $2.8B |
| FY Dec 2021 | $3.3B |
| Jun 2026 | $15.5M |
| Mar 2026 | $640.1M |
| Dec 2025 | $644.2M |
| Sep 2025 | $1.5B |
| Jun 2025 | $1.6B |
| Mar 2025 | $1.1B |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-755.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield VNRX
| FY Dec 2025 | -3.1% |
| FY Dec 2024 | -2.4% |
| FY Dec 2023 | -1.7% |
| FY Dec 2022 | -0.6% |
| FY Dec 2021 | -0.6% |
| Jun 2026 | -174.1% |
| Mar 2026 | -3.3% |
| Dec 2025 | -3.1% |
| Sep 2025 | -1.4% |
| Jun 2025 | -1.4% |
| Mar 2025 | -2.0% |
| Dec 2024 | -2.4% |
| Sep 2024 | -1.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing VNRX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $775.3K | $306.4K |
| Operating income | -$21.7M | -$27.0M | -$36.0M | -$31.8M |
| Net income | -$23.4M | -$27.0M | -$35.7M | -$30.6M |
| EPS (diluted) | n/a | -0.31 | -0.50 | n/a |
| Operating cash flow | -$19.7M | -$25.9M | -$18.1M | -$15.3M |
| Cash | $1.1M | $3.3M | $20.7M | $10.9M |
| Long-term debt | $5.8M | $4.0M | $3.6M | $2.8M |
| Buybacks | n/a | $0 | $31.8K | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
VNRX Stock Sonar score 4/7 axes
Find similar shapesCompareVNRX ranks highest on growth (73rd percentile) and risk and compliance (50th), and lowest on institutional and government (8th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VNRX filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 7.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
